Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

Blood (2023) 142 (19): 1647–1657.

https://doi.org/10.1182/blood.2023020649

Published: 2023

Includes: Supplemental data

Journal Articles

Clinical Characteristics and Outcomes of Therapy-Related Chronic Myelomonocytic Leukemia: Analysis of a Large Cohort

Alex Bataller, Georgina Gener-Ricos, Emmanuel Almanza, Samuel Urrutia, Kelly S. Chien, Danielle E. Hammond, Koji Sasaki, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Tapan M. Kadia, Rashmi Kanagal-Shamanna, Hagop M. Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood (2023) 142 (Supplement 1): 3237.

https://doi.org/10.1182/blood-2023-179979

Published: 2023

Journal Articles

Time-Limited Therapy with Zanubrutinib Plus Rituximab in Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase 2 Trial

Jan A. Burger, Ekaterina Kim, Mariela Sivina, Thomas Mathew, Danielle E. Hammond, Fadi G. Haddad, Alessandra Ferrajoli, William G. Wierda

Blood (2023) 142 (Supplement 1): 6524.

https://doi.org/10.1182/blood-2023-178774

Published: 2023

Journal Articles

Myeloid Neoplasia in Patients with Hereditary Hemoglobinopathies and Hemolytic Anemias (HHAs)

Miriam A. Osei, Lauren E. Merz, Kelly S. Chien, Danielle E. Hammond, Coleman Lindsley, Marlise R. Luskin, Maximilian Stahl, Joan How, Mohammed Wazir, Anna E. Marneth, Shai Shimony, Ann Mullally, Daniel J. DeAngelo, Guillermo Garcia-Manero, Maureen Okam Achebe, Benjamin L. Ebert, Lachelle D. Weeks

Blood (2023) 142 (Supplement 1): 2427.

https://doi.org/10.1182/blood-2023-172992

Published: 2023

Journal Articles

Azacitidine Plus Venetoclax Maintenance in Acute Myeloid Leukemia Produces Sustained Remissions with Low Toxicity: Results of a Phase 2 Study

Blood (2023) 142 (Supplement 1): 2884.

https://doi.org/10.1182/blood-2023-172882

Published: 2023

Journal Articles

ASXL1 / TET2 Genotype-Based Risk Stratification Outperforms ASXL1 Mutational Impact and Is Independent of Mutant Variant Allele Fractions (VAF) in CMML

Clifford M Csizmar, Mark Gurney, Rashmi Kanagal-Shamanna, Kelly S. Chien, Danielle E. Hammond, Terra L Lasho, Christy M Finke, Christopher Dean, Abhishek A Mangaonkar, Naseema Gangat, Ayalew Tefferi, Hassan Alkhateeb, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Mrinal M. Patnaik

Blood (2023) 142 (Supplement 1): 4615.

https://doi.org/10.1182/blood-2023-187235

Published: 2023

Journal Articles

Influence of Co-Mutational Patterns in Disease Phenotype and Clinical Outcomes of Chronic Myelomonocytic Leukemia

Blood (2023) 142 (Supplement 1): 4601.

https://doi.org/10.1182/blood-2023-178061

Published: 2023

Journal Articles

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 1857.

https://doi.org/10.1182/blood-2023-189557

Published: 2023

Journal Articles

Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 4616.

https://doi.org/10.1182/blood-2023-182256

Published: 2023

Journal Articles

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib: 2023 Update

Blood (2023) 142 (Supplement 1): 968.

https://doi.org/10.1182/blood-2023-182944

Published: 2023

Journal Articles

Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)

Emmanuel Almanza Huante, Alex Bataller, Danielle E. Hammond, Kelly S. Chien, Courtney D. DiNardo, Nicholas J. Short, Abhishek Maiti, Guillermo Montalban-Bravo, Farhad Ravandi, Guillermo Garcia-Manero, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 2922.

https://doi.org/10.1182/blood-2023-185191

Published: 2023

Journal Articles

Prognostic Relevance of Truncating ASXL1 Mutations and ASXL1 -Integrated Molecular Models in Proliferative CMML

Clifford M Csizmar, Mark Gurney, Terra L Lasho, Rashmi Kanagal-Shamanna, Kelly S. Chien, Danielle E. Hammond, Christy M Finke, Abhishek A Mangaonkar, Aref Al-Kali, Naseema Gangat, Ayalew Tefferi, Hassan Alkhateeb, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Mrinal M. Patnaik

Blood (2023) 142 (Supplement 1): 3241.

https://doi.org/10.1182/blood-2023-186881

Published: 2023

Journal Articles

Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms with FLT3 or CBL Mutations

Guillermo Montalban-Bravo, Elias Jabbour, Kelly S. Chien, Danielle E. Hammond, Nicholas J. Short, Farhad Ravandi, Marina Y. Konopleva, Gautam Borthakur, Naval Daver, Rashmi Kanagal-Shamanna, Wei Qiao, Xuelin Huang, Heather Schneider, Meghan Anne Meyer, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 3238.

https://doi.org/10.1182/blood-2023-178115

Published: 2023

Journal Articles

NPM1-Mutated Myeloid Neoplasms: Updated Outcomes with High-Intensive Chemotherapy Regardless of the Blast Percentage

Georgina Gener-Ricos, Alex Bataller, Emmanuel Almanza-Huante, Kelly S. Chien, Danielle E. Hammond, Koji Sasaki, Courtney D. DiNardo, Tapan M. Kadia, Naval Daver, Gautam Borthakur, Ghayas C. Issa, Nicholas J. Short, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood (2023) 142 (Supplement 1): 957.

https://doi.org/10.1182/blood-2023-187676

Published: 2023

Journal Articles

A Phase 2 Study of Canakinumab in Patients with Lower-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Juan Jose Rodriguez Sevilla, Vera Adema, Kelly S. Chien, Irene Ganan-Gomez, Guillermo Montalban-Bravo, Samuel Urrutia, Joby Joseph, Hui Yang, Gautam Borthakur, Nicholas J. Short, Ghayas C. Issa, Tapan M. Kadia, Koichi Takahashi, Danielle E. Hammond, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 1866.

https://doi.org/10.1182/blood-2023-185259

Published: 2023

Journal Articles

Characterization of MDS and CMML Patients Harboring Trisomy 8 Abnormality: Clinical, Autoimmune, and Mutational Features

Hussain Alcassab, Koji Sasaki, Danielle E. Hammond, Alex Bataller, David B Beck, Tapan M. Kadia, Guillermo Montalban-Bravo, Kelly S. Chien, L. Jeffrey Medeiros, Hagop Kantarjian, Awdesh Kalia, Manjunath Nimmakayalu, Carlos E. Bueso-Ramos, Guillermo Garcia-Manero, Rashmi Kanagal-Shamanna

Blood (2023) 142 (Supplement 1): 1881.

https://doi.org/10.1182/blood-2023-190464

Published: 2023

Journal Articles

Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria

Blood (2023) 142 (Supplement 1): 3228.

https://doi.org/10.1182/blood-2023-189203

Published: 2023

Journal Articles

Venetoclax (VEN) Improves Response Rates but Not Survival in Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents (HMA): A Multicenter, Propensity Score Analysis

Blood (2023) 142 (Supplement 1): 321.

https://doi.org/10.1182/blood-2023-181795

Published: 2023

Journal Articles

Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes

Guillermo Montalban-Bravo, Nicholas J. Short, Kelly S. Chien, Yesid Alvarado Valero, Naval Daver, Gautam Borthakur, Mahesh Swaminathan, Abhishek Maiti, Danielle E. Hammond, Graciela Nogueras-Gonzalez, Xuelin Huang, Heather Schneider, Kristen Shelly, Tapan M. Kadia, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 1876.

https://doi.org/10.1182/blood-2023-178035

Published: 2023

NARROW

Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

Clinical Characteristics and Outcomes of Therapy-Related Chronic Myelomonocytic Leukemia: Analysis of a Large Cohort

Time-Limited Therapy with Zanubrutinib Plus Rituximab in Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase 2 Trial

Myeloid Neoplasia in Patients with Hereditary Hemoglobinopathies and Hemolytic Anemias (HHAs)

Azacitidine Plus Venetoclax Maintenance in Acute Myeloid Leukemia Produces Sustained Remissions with Low Toxicity: Results of a Phase 2 Study

ASXL1 / TET2 Genotype-Based Risk Stratification Outperforms ASXL1 Mutational Impact and Is Independent of Mutant Variant Allele Fractions (VAF) in CMML

Influence of Co-Mutational Patterns in Disease Phenotype and Clinical Outcomes of Chronic Myelomonocytic Leukemia

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes

Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib: 2023 Update

Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)

Prognostic Relevance of Truncating ASXL1 Mutations and ASXL1 -Integrated Molecular Models in Proliferative CMML

Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms with FLT3 or CBL Mutations

NPM1-Mutated Myeloid Neoplasms: Updated Outcomes with High-Intensive Chemotherapy Regardless of the Blast Percentage

A Phase 2 Study of Canakinumab in Patients with Lower-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Characterization of MDS and CMML Patients Harboring Trisomy 8 Abnormality: Clinical, Autoimmune, and Mutational Features

Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria

Venetoclax (VEN) Improves Response Rates but Not Survival in Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents (HMA): A Multicenter, Propensity Score Analysis

Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only